ACTG vs BXC

ACTG exhibits severe financial health concerns, evidenced by a Piotroski F-Score of 2/9 (indicating weak fundamentals) and a missing Altman Z-Score, which raises distress risk concerns. Despite a Graham Number of $2.76 suggesting undervaluation, the stock trades at $4.88, implying a premium driven by speculative growth expectations. The company shows erratic earnings performance with massive EPS surprises, including a -2247% miss in 2022 and a 1587% beat in 2021, signaling extreme inconsistency. Profitability remains weak, with negative operating margins (-26.1%) and low ROE (4.31%), while revenue growth is minimal (2.6% YoY). The technical trend is bearish (10/100), and insider activity is neutral, offering no conviction.

BXC exhibits severe fundamental deterioration, characterized by a Piotroski F-Score of 4/9 (Stable) but offset by a catastrophic collapse in earnings power. The stock trades at a massive premium to its Graham Number ($5.94) and Intrinsic Value ($0.14), with a current P/E of 2917.50 reflecting near-zero profitability. While the balance sheet remains liquid with a Current Ratio of 4.66, the consistent failure to meet earnings estimates (0/4 beats) and a -175.8% YoY EPS growth indicate a business in a deep cyclical or structural decline.